CAPR stock rises nearly 5% as Capricor presents Deramiocel data
Capricor Therapeutics’ CAPR shares rose about 5% after the company presented clinical heart data for Deramiocel in Duchenne muscular dystrophy ahead of an anticipated November FDA decision.